(ZFGN) - Earnings & Price History

ZFGN: - 3.6, $98.39M, 0.04 (1.12%)

Sector: Healthcare - Industry: Biotechnology

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate is the Beloranib, an injection, which is in Phase III clinical trials for the treatment of obesity and hyperphagia in patients with Prader-Willi syndrome; that has completed Phase II clinical trials to treat hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity; and which has completed Phase IIb clinical trials for the treatment of severe obesity in the general population. The company is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor that is in pre-clinical studies for the treatment of nonalcoholic steatohepatitis and abdominal obesity, as well as other second-generation MetAP2 inhibitors to treat severe obesity. Zafgen, Inc. was founded

Past ZFGN reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-03-09-0.54.453.954.154.064.755.06%7.23%12.66%1.03M
2017-03-08-0.53.953.813.83.84.05-0.26%3.95%3.67%107.15K
2017-03-07-0.493.813.823.83.793.93-0.52%0.26%-0.26%5.46M
2016-11-09-0.613.453.433.513.383.622.33%▲-1.71%0.58%239.15K
2016-11-08-0.613.433.173.23.163.50.95%▲7.19%8.20%271.05K
2015-11-10-0.7912.111.6111.8711.7113.392.24%▲1.94%4.22%1.22M
2015-11-09-0.7911.6111.6211.3511.2111.82-2.32%▲2.29%-0.09%283.50K
2014-11-11AMCZafgen Inc-0.83-0.6519.2619.4319.4318.819.69-0.87%-0.87%17.70K
2014-08-13AMCZafgen Inc-0.29-2.9617.7317.8317.8517.517.90.11%-0.67%-0.56%9.00K

Login | Register
Friday Nov 16, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades